Hikma Pharmaceuticals Plc Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/27/2026)
| Balance Sheet | Total Assets | 5,680,070,000.00 | ROE | 45.72 % |
| Balance Sheet | Total Equity | 2,597,140,000.00 | ROA | 7.23 % |
| Cashflow | Capital Expenditures | -201,381,000.00 | P/FCF | 28.36 |
| Cashflow | Free Cash Flow | 165,603,008.00 | – | – |
| Cashflow | Operating Cash Flow | 436,000,000.00 | P/CF | 12.80 |
| Income | Earnings per Share (diluted) | 1.84 | Div. Yield | 3.99 % |
| Income | Net Income | 402,000,000.00 | P/E | 11.45 |
| Income | Shares Outstanding | 223,000,000.00 | P/B | 1.81 |
| Income | Total Revenue | 3,349,000,000.00 | P/S | 1.37 |
Ratios calculated on: 10/13/2026
Company Description
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.hikma.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more